X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Bintai obtained the right of first refusal to market and distribute the Ii-Key vaccine in Australia and New Zealand.
Lead Product(s): Ii-Key-SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bintai Kinden
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 23, 2020
Details:
The agreement incorporates the first Ii-Key platform project for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China.
Lead Product(s): Li-Key-SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $50.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement November 18, 2020
Details:
The paper describes why the Phase IIb clinical trial of AE37 in breast cancer demonstrated a statistically significant clinical benefit for certain subgroups of patients in the trial while failing to meet the primary endpoint in the entire intent-to-treat study population.
Lead Product(s): AE37 Peptide,Sargramostim
Therapeutic Area: Oncology Product Name: AE37
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The presentation revealed AE37 Ii-Key peptide vaccine is safe and associated with DFS in sub-sets of breast cancer survivors after 10-year follow-up .
Lead Product(s): AE37 Peptide,Sargramostim
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
Details:
Generex’s Ii-Key peptide vaccines for infectious disease and cancer have been studied in human clinical trials involving over 300 subjects in Phase I and Phase II clinical trials.
Lead Product(s): Ii-Key peptide vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2020
Details:
EpiVax to use Generex's computational tools to predict epitopes that can be used to generate peptide vaccines against the nCOV-2019 using the patented NuGenerex Immuno-Oncology .
Lead Product(s): Li-Key peptide vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: EpiVax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 05, 2020
Details:
NuGenerex Immuno-Oncology has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and aprevious coronavirus, SARS.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Beijing ZhonghuaInvestment Fund Management
Deal Size: $6.0 million Upfront Cash: $1.0 million
Deal Type: Collaboration February 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
